Will liquid biopsy ever be able to replace tissue biopsies?
Find out how close we are by registering for our latest webinar series: Liquid Biopsy ONLINE: Moving Towards Liquid First, Where Innovation Meets Care. This series will move beyond theory into practical advice and lessons learned to improve the detectability of analytes, infrastructure set up, and analysis of liquid biopsies.
Register to the Liquid Biopsy ONLINE webinar here
**Please note that by registering for the first webinar in the series you will automatically gain access to the subsequent webinars in the series**
By attending this webinar series, you will:
- Gain an understanding of the detectable biomarkers in a liquid biopsy, their isolation and detection, and the limitations this presents for utility.
- Get practical tips to optimise liquid biopsy workflows – improving your chance of detection in a sample. Hear about the downstream clinical utility of liquid biopsies and the future of this work.
- Discover the truth behind implementation – including cost and time savings compared to standard tissue biopsies, infrastructure building and potential patient benefit.
This webinar series will be jam-packed with practical advice to improve the likelihood of success in liquid biopsy research and with its ultimate translation.
Register now by clicking here
Webinar 1: Exploring Detectable Biomarkers in Liquid Biopsies
Tuesday 29th October at 3pm GMT/ 4pm CET/ 10am EST
Advances in omics technologies have expanded the range of circulating biomarkers at our disposal. The ability to isolate and stabilise multiple analytes from a single blood draw opens the exciting possibility to use novel biomarkers in clinical settings.
In this webinar, we will delve into the biology of circulating biomarkers, including cfDNA, RNA and the possibility of modulating biology with priming agents. We will discuss their clinical significance, the challenges associated with their isolation and analysis, and the potential solutions to enhance their future utility as clinical biomarkers.
Modulating cfDNA biology: Inhibiting cfDNA Clearance via Priming Agents to Improve Liquid Biopsies
- Shervin Tabrizi, Attending Physician, Massachusetts General Hospital
Using cfDNA Derived From Pleural Effusion to Diagnose Cancers Affecting The Lung
- Antonia Pritchard, Reader, University of the Highlands and Islands
Advancing RNA Liquid Biopsy Technology
- Daniel Kim, Assistant Professor, UC Santa Cruz
Webinar 2: Optimising The Liquid Biopsy Workflow
Tuesday 5th November at 3pm GMT / 4pm CET / 10am EST
A major challenge in liquid biopsy adoption is the need to reliably detect and analyse biomarkers, whilst minimising false results.
This webinar will focus on standardising workflows, from sample collection and stabilisation to results, to minimise these errors. It will also cover the analysis and bioinformatics tools that are improving sensitivity for the detection and interpretation of ultra-rare variants in liquid biopsies.
You will leave the webinar with practical tips to optimise the likelihood of successful liquid biopsy analyses.
Optimising Liquid Biopsies for Therapy-Relevant ESR1 Mutations in Breast Cancer
- Franziska Fahlteich, Research Assistant, University Hospital Carl Gustav Carus
Pre-Analytical Pitfalls and the Power of Standards: Why ISO for Liquid Biopsies Matters
- Amin El-Heliebi, Principal Investigator, Medical University of Graz
Harnessing The Power of dPCR For Multiplex Analysis of Copy Number Variant in Liquid Biopsies in Solid Tumours
- Stefania Crucitta, Junior Researcher, University of Pisa
Tuesday 12th November at 3pm GMT /4pm CET/ 10am EST
This webinar will explore the implementation of liquid biopsies in clinical care, highlighting where they are making the most significant impact and strategies for overcoming barriers to their routine use, including assessing health economics.
We will cover the application of liquid biopsies in identifying cancer variants, monitoring disease progression, and assessing treatment response. We will also discuss the tools and infrastructure needed for liquid biopsy analysis, and the potential cost-savings and patient benefit of widespread liquid biopsy adoption.
Liquid Biopsy-Based Tests for Early Detection and Monitoring of Cancer – Experience with Clinical Studies
- Hege Marie Vedeld, Post-doc, Oslo University Hospital
Lessons Learned From the National Lung Cancer ctDNA Pilot
- Alastair Greystoke, Professor of Precision Oncology and Honorary Consultant in Medical Oncology, Newcastle University
The Benefits of Circulating miRNAs in Liquid Biopsies
- Matthew Murray, Honorary Consultant Paediatric Oncologist, Cambridge University Hospitals NHS Foundation Trust
